Cantor Fitzgerald Reiterates Overweight on Arcus Biosciences, Maintains $46 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Alethia Young has reiterated an Overweight rating on Arcus Biosciences (NYSE:RCUS) and maintained a $46 price target.
September 07, 2023 | 3:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Arcus Biosciences and maintained a $46 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Arcus Biosciences. The maintained price target of $46 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100